319 related articles for article (PubMed ID: 26833336)
1. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
3. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
4. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
7. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X;
J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930
[TBL] [Abstract][Full Text] [Related]
8. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
13. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).
Barouch DH; Liu J; Peter L; Abbink P; Iampietro MJ; Cheung A; Alter G; Chung A; Dugast AS; Frahm N; McElrath MJ; Wenschuh H; Reimer U; Seaman MS; Pau MG; Weijtens M; Goudsmit J; Walsh SR; Dolin R; Baden LR
J Infect Dis; 2013 Jan; 207(2):248-56. PubMed ID: 23125443
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
15. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).
Baden LR; Walsh SR; Seaman MS; Tucker RP; Krause KH; Patel A; Johnson JA; Kleinjan J; Yanosick KE; Perry J; Zablowsky E; Abbink P; Peter L; Iampietro MJ; Cheung A; Pau MG; Weijtens M; Goudsmit J; Swann E; Wolff M; Loblein H; Dolin R; Barouch DH
J Infect Dis; 2013 Jan; 207(2):240-7. PubMed ID: 23125444
[TBL] [Abstract][Full Text] [Related]
16. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
[TBL] [Abstract][Full Text] [Related]
17. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
18. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Salisch NC; Stephenson KE; Williams K; Cox F; van der Fits L; Heerwegh D; Truyers C; Habets MN; Kanjilal DG; Larocca RA; Abbink P; Liu J; Peter L; Fierro C; De La Barrera RA; Modjarrad K; Zahn RC; Hendriks J; Cahill CP; Leyssen M; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
Ann Intern Med; 2021 May; 174(5):585-594. PubMed ID: 33587687
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH; Brown D; Kublin J; Monahan K; Wright DP; Lalezari J; Santiago S; Marmor M; Lally M; Novak RM; Brown SJ; Kulkarni P; Dubey SA; Kierstead LS; Casimiro DR; Mogg R; DiNubile MJ; Shiver JW; Leavitt RY; Robertson MN; Mehrotra DV; Quirk E;
Clin Infect Dis; 2008 Jun; 46(11):1769-81. PubMed ID: 18433307
[TBL] [Abstract][Full Text] [Related]
20. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.
Baden LR; Liu J; Li H; Johnson JA; Walsh SR; Kleinjan JA; Engelson BA; Peter L; Abbink P; Milner DA; Golden KL; Viani KL; Stachler MD; Chen BJ; Pau MG; Weijtens M; Carey BR; Miller CA; Swann EM; Wolff M; Loblein H; Seaman MS; Dolin R; Barouch DH
J Infect Dis; 2015 Feb; 211(4):518-28. PubMed ID: 25165165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
